Hlavní stranaMezinárodní biotech událostiBiosimilars & Biobetters 2017

Biosimilars & Biobetters 2017


Holiday Inn Kensington Forum, London UK (September, 27 - 28, 2017)

SMi Group are thrilled to present the 2017 8th annual conference on Biosimilars & Biobetters taking place on 27th & 28th September in Central London, UK.


As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms creating a rapidly booming biosimilars market. However, as the field of biosimilars evolves, challenges in immunogenicity studies, securing market share, exclusivity and regulations still persist.

Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and critical updates on interchangeability guidelines and patient litigation.

A must attend for principle scientists and regulatory experts involved in biotechnology, market access and compliance, Biosimilars & Biobetters 2017 will capture expert insight by honing in on current market trends through to emerging opportunities and global developments.




                     Bernd Liedert, Senior Clinical Program Leader Biosimilars, Boehringer Ingelheim

                     Ho-Ung Kim, Division Head Strategy and Operations, Celltrion Healthcare

                     Sarah Rickwood, Vice President, Head of European Thought Leadership, QuintilesIMS

                     Matthew Turner, Global Medical Director, Biosimilars, Merck Group

                     Steiner Madsen, Medical Director, Norwegian Medicines Agency

                     Thomas Sachnik, Senior Manager Strategic Associate to the President & CEO Generics Europe, Teva Pharmaceuticals

                     Harish Pai, Principal Scientific Manager, Biocon

                     Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter

                     Glenn Kazo, President & COO, Prolong Pharmaceuticals

                     Richard Peck, Vice President Regulatory Affairs, Lupin Europe




                     Gain an overview of the latest developments in regulation to increase speed of entry and compliance through informed guidance on interchangeability laws, patient litigation and IP rules

                     Develop strategies for market access and expansion by identifying key changes and future projections in biosimilars

                     Evolve clinical developments through insight into orphan drugs, in-vitro functional assays and data extrapolation

                     Create a competitive edge through understanding the multifaceted field of "switching studies"

                     Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests

                     Discuss challenges and potential solutions in exclusivity and HCP acceptance

                     Get unique coverage of biobetters from companies specialising in this field


For further details or to register, visit the website at http://www.biosimilars-europe.com/gate2biotech or contact Fateja Begum on +44 (0)20 7827 6184, email fbegum@smi-online.co.uk

Více: http://www.biosimilars-europe.com/gate2biotech

Czech Bio

CEBIO a I. etapa JVTP

  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina


Jihočeská agentura pro podporu inovačního podnikání o.p.s.

Články na přání

[načítám anketu]